Jiangsu CoWin Biotech Co., Ltd. (SHA:688426)

Market Cap	2.09B
Revenue (ttm)	125.88M
Net Income (ttm)	-157.21M
Shares Out	111.14M
EPS (ttm)	-1.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	686,142
Average Volume	946,849
Open	17.49
Previous Close	17.38
Day's Range	17.02 - 17.65
52-Week Range	14.81 - 32.06
Beta	0.67
RSI	51.31
Earnings Date	Apr 25, 2025

About Jiangsu CoWin Biotech

Jiangsu CoWin Biotech Co., Ltd. engages in the research and development, production, and sale of biological products in China. The company provides molecular diagnostic raw material enzymes, nucleic acid collection and protection agents, nucleic acid extraction and purification kits, molecular diagnostic testing reagents, etc. It also offers medical device products, nucleic acid collection and protection, PCR, RT-PCR, and qPCR products, molecular diagnosis, isothermal amplification, nucleic acid mass spectrometry, next generation sequencing, nu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 657
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688426

Financial Performance

In 2024, Jiangsu CoWin Biotech's revenue was 125.88 million, a decrease of -26.54% compared to the previous year's 171.34 million. Losses were -157.21 million, 86.2% more than in 2023.